<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103282</url>
  </required_header>
  <id_info>
    <org_study_id>PuraStat-002-VASC</org_study_id>
    <nct_id>NCT03103282</nct_id>
  </id_info>
  <brief_title>Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery.</brief_title>
  <official_title>A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding In Vascular Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3-D Matrix Europe SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3-D Matrix Europe SAS</source>
  <brief_summary>
    <textblock>
      The objective of this post-market clinical follow-up study is to collect medical information
      on patients implanted with PuraStat®, according to each participating institution's
      procedures and standards of care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Time-To-Haemostasis</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Total Time-To-Haemostasis will be intraoperatively measured (minutes, seconds)</description>
  </primary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Vascular Anastomosis Surgery</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PuraStat®</intervention_name>
    <description>Synthetic haemostatic material</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been previously treated with PuraStat®
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main Inclusion criteria:

          1. Male or female patient ≥18 years old

          2. Subject undergoing elective carotid endarterectomy either with patch reconstruction or
             eversion technique

          3. Subject who is able to give voluntary, written informed consent to participate in this
             clinical study and from whom consent has been obtained

          4. Subject, who, in the opinion of the Clinical Investigator, is able to understand this
             clinical study, cooperate with the study procedures and is willing to return for the
             required post-treatment follow-up

        Main exclusion criteria:

          1. Presence or sequelae of coagulation disorder

          2. Known allergy or hypersensitivity to any component of PuraStat®

          3. Concurrent participation in another clinical trial with a medical device or a
             medicinal product

          4. Pregnant or interested in becoming pregnant during the duration of the study, or
             breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Caroline LEBLANC</last_name>
    <email>cleblanc@puramatrix.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

